Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma clinical trials recruiting in the U.S.
23 studies for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH5 studies
- Philadelphia, PA4 studies
- Washington, DC4 studies
- Boston, MA3 studies
- Baldwin Park, CA3 studies
- St. Louis, MO3 studies
- New Rochelle, NY3 studies
- Staten Island, NY3 studies
- Queens, NY3 studies
- Edison, NJ3 studies
- East Norwalk, CT3 studies
By state
- California5 studies
- Colorado3 studies
- Florida3 studies
- Massachusetts3 studies
- Missouri3 studies
- New Jersey3 studies
- New York7 studies
- North Carolina3 studies
- Ohio6 studies
- Pennsylvania5 studies
- Tennessee3 studies
- Texas8 studies
Recently updated studies
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Sep 29, 2026 · NCT06904066A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RecruitingPhase 2
6 Months · All sexes · Updated Sep 28, 2026 · NCT06514794Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT04301076Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT01087333A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
RecruitingPhase 2
1 Month – 21 Years · All sexes · Updated Sep 18, 2026 · NCT06561074Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT05289687Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
RecruitingPhase 1
Up to age 39 · All sexes · Updated Sep 11, 2026 · NCT04972942Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
RecruitingPhase 1
Ages 12 to 30 · All sexes · Updated Aug 12, 2026 · NCT07513129Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
RecruitingPhase 1
Up to age 75 · All sexes · Updated Aug 11, 2026 · NCT03081910Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Aug 10, 2026 · NCT06390319Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
RecruitingPhase 2
All ages · All sexes · Updated Jul 15, 2026 · NCT00501826Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
RecruitingPhase 1
Ages 0 to 29 · All sexes · Updated Jul 7, 2026 · NCT06934382Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Registry for People With T-cell Lymphoma
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04318678Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
RecruitingPhase 1
Up to age 75 · All sexes · Updated May 18, 2026 · NCT07220993Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT05996185A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT06698003Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 10, 2026 · NCT04848064Two Step Haplo With Radiation Conditioning
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.